Single B Cell Technology: SPIN Advancements
Enhance your success in antibody discovery with our SPIN® Technology, which incorporates single B cell technology, granting the capability to select desired rare antibodies directly from affinity-matured plasma cells.
High-throughput screening has enabled interrogation of the natural antibody repertoire. Our proprietary Single Plasma Cell Interrogation (SPIN®) platform uses microfluidic technology to isolate antigen-specific plasma cells and single-cell technology to analyze native paired antibody genes.
Immunization
· Identify and isolate antigen specific plasma cells
· Gating only higher affinity cell population while performing FACS sorting
· Isolate antibodies which cross to orthologous protein amongst species and homologues protein within species
· Increase specificity by counter-selecting antibodies which cross to non-relevant homologous target or exclude structurally similar targets
Functional analysis
· Multi-species immunization
· Diversity of antigens: glycans, small molecules, post-translational modifications or single amino acid substitution
· Proprietary carrier proteins to enhance immunogenicity of weak antigen targets
Single Plasma Cell Screening
· Kinetic analysis and Epitope binning to pick lead antibodies with confidence
· IHC analysis, flow cytometry, functional analysis (EC50 and IC50)
Paired expression and ELISA screening
· Native pairing of heavy and light chains
· Early stage screening: Standard ELISA, SPR, Affinity ranking, epitope mapping
Benefits of SPIN®
High affinity
Antibody genes amplified from terminal differentiated plasma cells with native pairs of heavy chain and light chain ensure high affinity of antibodies.
Diverse selection of species
Because of the diverse nature of the SPIN® platform, any immunized animals or vaccinated humans can be analyzed for monoclonal antibody development.
Broad diversity
There is no bias during the process of single plasma cell isolation and functional selection.
Quick turnaround
SPIN® technology shortens the monoclonal antibody development timeline from 4 months to 4 weeks.
Benefits of SPIN®
Diverse selection of species
Because of the diverse nature of the SPIN® platform, any immunized animals or vaccinated humans can be analyzed for monoclonal antibody development.
Broad diversity
There is no bias during the process of single plasma cell isolation and functional selection.
High affinity
Antibody genes amplified from terminal differentiated plasma cells with native pairs of heavy chain and light chain ensure high affinity of antibodies.
Quick turnaround
SPIN® technology shortens the monoclonal antibody development timeline from 4 months to 4 weeks.